* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on February
26 for the period ending December 31 2024
* The South Jordan Utah-based company is expected to report
a
6.1% increase in revenue to $79.667 million from $75.08 million
a year ago, according to the mean estimate from 14 analysts,
based on LSEG data.The company's guidance on November 6 2024,
for the period ended December 31, was for revenue between $78.00
million and $84.00 million.
* LSEG's mean analyst estimate for Health Catalyst Inc is
for
earnings of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $9.50, above its last closing price of $5.23.
The company's guidance on November 6 2024 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD78 million and
USD8.8 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 0.10 0.10 0.07 Missed -28.3
Jun. 30 2024 0.09 0.08 0.12 Beat 51.3
Mar. 31 2024 0.03 0.03 0.05 Beat 79
Dec. 31 2023 0.01 0.00 0.02 Beat 2,700
Sep. 0.00 -0.02 0.03 Beat 275.6
30 2023
Jun. 30 2023 -0.01 0.00 0.05 Beat 1,447.
7
Mar. 31 2023 -0.04 -0.04 0.05 Beat 222.9
Dec. 31 2022 -0.11 -0.11 -0.05 Beat 55.8
This summary was machine generated February 24 at 21:30 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)